Ortho-Clinical Diagnostics, Inc. Announces Executive Leadership Additions as It Becomes an Independent, Stand-Alone Company
July 08 2014 - 8:00AM
Business Wire
New Management Team in Place to Drive
Growth
Today Ortho-Clinical Diagnostics, Inc. (OCD) unveiled its newly
expanded executive leadership team following the acquisition of the
company by The Carlyle Group (NASDAQ: CG) from Johnson &
Johnson. In his first act as OCD Chairman and Chief Executive
Officer, Dr. Martin D. Madaus announced key appointments in
finance, operations, legal and commercial to advance strategic
sectors of the In Vitro Diagnostics (IVD) business.
“We have recruited top industry talent, recognized for their
global diagnostics expertise, to build a revitalized, stand-alone
company," said Dr. Madaus. “Under their leadership, OCD will be
positioned to grow, enhance its industry-leading medical
diagnostics products and services, and innovate with new,
diagnostic solutions through targeted investment."
In February, The Carlyle Group announced that Dr. Madaus would
lead OCD after the acquisition. Dr. Madaus has leveraged his
business acumen and more than 25 years of experience in the
diagnostics and life sciences industries to lay the groundwork for
an independent OCD. Dr. Madaus and OCD will have a central focus on
ensuring a seamless transition for customers. Today, the company
announced the following appointments:
- Alex Socarras, Executive Vice
President, Commercial
Mr. Socarras has strong commercial and
general management experience in diagnostics in the U.S., Latin
America and Europe. Prior to joining Ortho Clinical Diagnostics,
Mr. Socarras was a senior vice president and CEO of healthcare in
South West Europe at Siemens Healthcare. He also served as their
vice president and region CEO of Latin America.
- Robert Yates, Chief Operating
Officer
Mr. Yates has extensive senior leadership
experience delivering significant commercial and business successes
in diagnostics and life sciences. He joins Ortho Clinical
Diagnostics from EMD Millipore, where he served as president and
CEO, leading the company through a period of outstanding growth.
Prior to EMD Millipore, Mr. Yates was the head of life sciences,
diagnostics business development and U.S. operations at Roche
Diagnostics.
- Jeffrey D. Capello, Chief Financial
Officer
Mr. Capello has demonstrated a consistent
record of improving the operational and financial health of global
organizations across multiple industries. He was most recently
Executive Vice President and Chief Financial Officer at Boston
Scientific and has more than 29 years of experience in various
roles in which he drove operational improvement and implemented
strategies to drive value.
- Michael Schlesinger, General
Counsel
Mr. Schlesinger has extensive experience in
corporate practice and M&A, and provided in-house counsel for a
variety of venture-backed firms. As a former partner and corporate
lawyer at Latham & Watkins, LLP, he has more than 25 years of
experience representing numerous companies in a variety of business
transactions including, acquisitions, sales, mergers, joint
ventures and divestitures.
About Ortho-Clinical Diagnostics, Inc.
Ortho-Clinical Diagnostics, Inc. delivers high-quality in vitro
diagnostic products that give healthcare professionals around the
world the knowledge they need to make better treatment decisions
sooner. The company serves the global transfusion medicine
community with donor screening and blood typing products to help
ensure every patient receives blood that is safe, the right type
and the right unit. Ortho-Clinical Diagnostics, Inc. also brings
sophisticated information management, testing technologies and
automation and interpretation tools to clinical laboratories
worldwide to help them run more efficiently and improve patient
care. For more information, visit www.orthoclinical.com.
MEDIA:Ortho-Clinical Diagnostics, Inc.Stephanie
ScottOffice: (908) 218-8137Cell: (908) 720-6859
Carlyle (NASDAQ:CG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Carlyle (NASDAQ:CG)
Historical Stock Chart
From Jul 2023 to Jul 2024